SUMMARY Background
Treatment of IBS and functional lower gastrointestinal disorders is still based predominantly on symptoms; biomarkers that reflect the mechanism or pathophysiology have been identified. Given the diverse mechanisms that result in the same clinical phenotype of IBS, it is hypothesised that identification of biomarkers may lead to individualisation of medical therapy.
Aim
To review the biomarkers that have been appraised in IBS.
Methods

A single author reviewed the published literature on biomarkers appraised in IBS.
Results
The current literature suggests that these biomarkers are insufficiently sensitive or specific to differentiate IBS from health or from other diseases causing similar symptoms, such as coeliac disease or inflammatory bowel disease. Most of the proposed biomarkers are not actionable, that is, they do not lead to an efficacious therapy based on the biological inference of the biomarker itself. However, among proposed biomarkers in IBS, some are actionable, as they specifically reflect a quantitative difference in a mediator of dysfunction or result in a quantifiable disturbance of function that can be specifically treated. Such biomarkers may potentially identify relevant subgroups that respond to specific therapy. The most promising actionable biomarkers are measurement of colonic transit (leading to treatments that reverse the abnormal transit) and measurements of bile acid diarrhoea to identify responders to bile acid sequestrants.
Conclusions
Therefore, although biomarkers are not ready for prime time as diagnostic tests in IBS, some biomarkers could identify subgroups of patients with IBS for inclusion in clinical trials that target specific dysfunctions. Such an approach may enhance treatment efficacy, and may ultimately help reduce costs in drug development and in the management of patients in clinical practice. 
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INTRODUCTION
Irritable bowel syndrome (IBS) is a highly prevalent disease in most countries
1 that is generally identified on the basis of symptoms 2 and exclusion of organic diseases.
Symptoms may vary between subtypes of IBS, in particular, bowel function; thus, consensus criteria discern IBS with constipation, diarrhoea, mixed bowel function or unspecified. In addition, the symptom complex may vary over time in the same patient with functional gastrointestinal disorders. 3 The identification of perturbations of gastrointestinal motor, immune, barrier and sensory functions in IBS provides potential biomarkers based on those functions, rare genetic mutations (as in GUCY2C) associated with functional diarrhoea, changes in tissue expression and therapeutic responses. 4 These biomarkers may provide an opportunity to diagnose, prevent or reverse symptoms of IBS.
Definition and required characteristics of a biomarker A valid biomarker is defined as 'a characteristic that is measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention'.
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A useful IBS biomarker would be expected to enhance one or more of the following: improve diagnosis, predict prognosis, discriminate patients with IBS from healthy individuals and from other organic diseases, reduce disease-related costs, identify relevant subgroups responding to specific therapy, identify subgroups of patients for inclusion in clinical trials, enhance drug development and monitor drug efficacy. 6 Based on current evidence, it was recently suggested that biomarkers for IBS were not ready for prime time. 7 One of the challenges in appraising the validity of biomarkers in IBS is that there is no current gold standard for the diagnosis of IBS; in addition, the heterogeneity of the condition implies that any biomarker is unlikely to have optimal sensitivity and specificity in all phenotypic subgroups. This review addresses the potential for these diverse traits to identify ways to diagnose, prevent or reverse symptoms of IBS, 4, [6] [7] [8] [9] akin to the biomarker revolution in oncology. The need for developing and validating biomarkers in IBS stems from the weak pooled sensitivity and specificity for symptoms in diagnosing IBS 9 and the relatively small proportion of responders to approved therapies, based on trials anchored by bowel function phenotype. For example, Sood et al. 9 estimated the specificity of lower abdominal pain is 32% (95% CI: and the specificity for sense of incomplete rectal evacuation is 45% (95% CI: 31-60). In addition, the 'diagnostic' symptom-based Rome III criteria had sensitivity of 68.8% (95% CI: 63.8-73.3) and specificity of 79.5% (95% CI: 77.4-81.5). In addition, in IBS therapeutic trials, active treatments are associated with at most 70% efficacy with a background of~50% response to placebo. Thus, an important question arises: Are there valid biomarkers that could be applied in IBS to improve diagnosis or enhance therapy to prevent or reverse symptoms of IBS, like the biomarker revolution in oncology? This review concludes that there are actionable biomarkers that are ready for application to identify IBS subgroups and optimise their treatment.
Single or combination biomarkers for diagnosis of IBS?
To date, a wide spectrum of individually appraised markers based on serological, immune or sensation traits has not had sufficient sensitivity or specificity to achieve the discriminatory goals required of a valid biomarker for diagnostic purposes. 7, 9 Therefore, one approach has been to pool different markers. For example, the diagnostic performance of a pool of 10 serum biomarkers [including markers of pain, 5-hydroxytryptamine (5-HT) metabolism, mast cell activation and inflammation] was disappointingly poor and improved only when the original list was extended to 34 serological and gene expression markers for differentiating IBS from health (AUC = 0.81), or IBS-C (constipation) vs. IBS-D (diarrhoea) (AUC = 0.92). 10 This differentiation of IBS from health improved further with the addition of four psychological markers (combined AUC = 0.93); 10 however, psychological variables provided almost no incremental discrimination for identifying IBS-C compared to IBS-D. Figure 1 shows a summary of potential etiologic mechanisms or quantitative variables that have been proposed as diagnostic biomarkers in IBS (reviewed in references [7] [8] [9] 11 ).
The sensitivity and specificity of these markers to differentiate IBS from health or other functional gastrointestinal diseases (FGIDs) or inflammatory bowel diseases have been reviewed elsewhere. 9 Unfortunately, for all these markers, specificity is relatively low at high sensitivity and vice versa. Three recently published studies propose diverse approaches.
El-Salhy et al. suggested that densities of rectal peptide YY and somatostatin cells may be useful biomarkers for the diagnosis of IBS. In an analysis of 101 patients with IBS based on Rome III criteria, and 62 healthy subjects who underwent rectal biopsy immunostaining for PYY and somatostatin, the density of PYY cells was significantly lower in IBS patients, with an area under the ROC curve (AUC) of 0.99, whereas somatostatin cell density was higher in IBS patients than in the controls (AUC of 0.86). 13 In a third recent paper, Casen et al. examined 54 DNA probes targeting ≥300 bacteria in faecal samples on different taxonomic levels based on ability to distinguish between healthy controls and IBS patients. Thus, 165 healthy controls (normobiotic reference collection) were used to develop a dysbiosis model with a bacterial profile and Dysbiosis Index Score output. Dysbiosis was detected in 73% of IBS patients, in 70% of treatmentna€ ıve IBD patients, and in 80% of IBD patients in remission, vs. 16% of healthy individuals. The authors claimed that the test provides insight into a patient's intestinal microbiota, and they speculate that evaluating microbiota as a diagnostic strategy may allow monitoring of prescribed treatment regimens and improvement in new therapeutic approaches.
14 Unfortunately, no data were available to support this speculative claim. It is relevant to note that, for most of the markers, there is no specific or validated treatment that, when directed at the marker (such as tight junction disruption or faecal secretogranin or serum levels of anti-CdtB), would result in restoration of normal function or relief of symptoms. Although measurements of small bowel permeability improved with gluten withdrawal from the diet, and this was associated with a reduced frequency of bowel movements in a randomised controlled trial of 45 IBS-D patients, especially in HLA-DQ2/8 carriers, 15 measurement of intestinal permeability alone or in combination with other traits (colonic transit and faecal bile acid excretion) did not significantly contribute to the discrimination between health and IBS or IBS-C from IBS-D.
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Is the biomarker prevalent and actionable?
The relative prevalence of a biomarker will clearly influence its performance from a diagnostic perspective (in the discrimination of health and organic diseases), but even if not omnipresent, it may identify a subgroup of patients with an actionable phenotype. Thus, even though the prevalence in IBS of visceral sensitivity ranges, in published series from tertiary centres, from 20 to~95%, the identification of rectal hypersensitivity would be highly relevant if there was an effective visceral analgesic therapy. Similarly, although only 20% of IBS-C and 45% of IBS-D patients have, respectively, significantly delayed or accelerated colonic transit, 16 ). Most of these findings on RNA sequencing were confirmed on RT-PCR. In addition, in a study of rectosigmoid mucosa from 47 patients with IBS-D compared to 17 healthy controls, mRNA expression of GUC2AB and PDZD3 (involved in ion secretion) was increased, whereas, mRNA expression of CLDN1 and FN1 (both tight junction proteins) was decreased. These changes were not identified in mucosal biopsies from 10 patients with IBS-C in whom there were increased fold expressions of P2RY4, VIP and occludin relative to the healthy controls.
In a study of mRNA expression in colonic mucosa in 12 patients with chronic constipation and 12 healthy controls (all female), there were no significant group differences in expression of the GC-C receptor or endogenous GC-C receptor agonists (guanylin and uroguanylin), or expression of the cGMP transporter proteins. However, there was significant negative correlation between levels of expression of guanylin protein (endogenous ligand of guanylate cyclase C receptor resulting in chloride and water secretion) and current overall GI symptom severity in patients with chronic constipation (r = À0.701, P = 0.024). 28 These differential mucosal expressions represent potential biomarkers of mechanisms resulting in the common symptom phenotype, such as increased expression of uroguanylin presumed from the increased mRNA expression of GUCA2B in IBS-D, and reduced protein levels of guanylin protein in patients with chronic constipation. Further validation of these biomarkers may provide targets for individualised therapy in patients with IBS-C or IBS-D, such as guanylate cyclase C agonists or chloride channel activators for IBS-C with reduced guanylin protein levels, or tenapanor, a minimally absorbed small molecule inhibitor of NHE3 which is a transporter of sodium in patients with IBS-C that bypasses the chloride secretory pathway in the enterocyte (reviewed in ref. 29 ).
Genetic influence of response to IBS therapy: biomarker in pharmacogenetics
There are a few examples in the published literature suggesting that genetic variants may serve as biomarkers to identify patients with differential responses to pharmacological therapies.
(i) There is evidence that circulating 5-HT levels are increased in patients with IBS-D or post-infectious IBS, but reduced in patients with IBS-C. 30, 31 Since 95% of the body serotonin is located in the gut, it is considered that the circulating levels reflect the gut tissue levels of serotonin. Genetic variation in 5-HTTLPR, the gene that determines the level of 5-HT at serotonergic synapses, has been demonstrated to affect responses to therapy in IBS. Thus, reduced 5-HT at synapse associated with the long polymorphic repeat (LL genotype) which is associated with high levels of transcription of the 5-HT re-uptake protein, SERT, results in enhanced colonic transit response (slowing) to the 5-HT 3 antagonist, alosetron, in IBS-D. The interpretation of these data is that, in the presence of high levels of SERT, there is greater re-uptake of 5-HT in the synapse and, therefore, less endogenous 5-HT that needs to be inhibited from activating the post-synaptic receptor. 32 There is also evidence that the 5-HTTLPR genotype impacts the response to another 5-HT 3 receptor antagonist, ondansetron. Thus, the SL genotype was borderline associated (P = 0.07) with effects on change in stool consistency and whole gut transit time in an analysis of 87 patients in a placebo-controlled, crossover study of 5 weeks of ondansetron, 4mg (dose titration allowed). 33 Conversely, the short (by 44bp) polymorphic repeat in 5-HTTLPR, which results in reduced transcription of SERT protein, is associated with greater efficacy, measured as symptomatic benefit of tegaserod in IBS-C. The interpretation of these data is that, with less SERT transcribed, less 5-HT is taken up in the synapse, leaving more 5-HT available to stimulate serotonergic receptors such as 5-HT 3 and 5-HT 4 receptors. Stimulation of these receptors results in the release of acetyl choline from cholinergic neurons, enhancing the effects of the exogenous 5-HT 4 receptor agonist, tegaserod.
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These pharmacogenomics interactions with 5-HTTLPR are illustrated in Figure 2 .
(ii) Klotho-ß (KLB) and fibroblast growth factor receptor 4 (FGFR4) are proteins that mediate feedback inhibition of hepatocyte bile acid (BA) synthesis by fibroblast growth factor 19 (FGF-19) reaching the liver from the portal circulation. Variants of KLB and FGFR4 influence colonic transit in patients with IBS-D; 35 in addition, FGFR4 rs351855 and KLB rs497501 coding variants influenced the colonic transit response to the BA sequestrant, colesevelam, 1.875 g b.d., compared to placebo in 24 female IBS-D patients. Thus, FGFR4 rs351855 and KLB rs497501 were associated with differential effects of colesevelam on ascending colon half-emptying time (t 1/2 ) and on overall colonic transit at 24 h, suggesting that these SNPs may identify a subset of IBS-D patients with beneficial response to colesevelam. 36 (iii) CNR1 (cannabinoid type 1 receptor) rs806378 CT/TT genotype is associated with a modest delay in colonic transit at 24 h compared with CC (P = 0.13) for differential treatment effects on post-minus pre-treatment changes in colonic transit by genotype. 37 
Brain imaging as a potential biomarker
The literature on brain or regional (e.g. insula) connectivity in patients with IBS or chronic abdominal pain suggests that there are significant associations with symptoms. [38] [39] [40] Structural and functional alterations in brain regions of the salience, emotional arousal and sensorimotor networks, as well as in the prefrontal region, show moderate correlations with behavioural and clinical measures. 41 In addition, although not currently generalisable or easily applied in clinical practice, brain imaging can relate to targets for therapy, can be actionable, and may predict responsiveness to therapy. Thus, the association of resting connectivity with psychological disturbances (including early life events 42 and emotional stress) could be targets for psychological or psychotropic treatment. Responsiveness in the brain imaging biomarker to brain-directed treatments is illustrated by several examples:
(i) Improvement with hypnosis treatment is associated with differential brain imaging effects in hypnosis responders; 43 (ii) Brain imaging abnormalities in the cingulate region reverted to normal in response to behavioural and psychotropic treatment that was associated with clinical improvement; 44 (iii) Neurodegeneration observed in stress, depression or brain trauma 45, 46 in patients with chronic pain and IBS can potentially reverse with psychotropic treatment. These preliminary observations on brain imaging require replication and would be most impactful if less expensive and more accessible methods are developed for use in patients with lower FGID.
Are any biomarkers ready for prime time in diagnosis or treatment of lower FGID? Barbara and Stanghellini suggested that there are no biomarkers ready for application in routine clinical care in IBS. 7 The literature certainly supports this conclusion relative to diagnostic biomarkers, that is, the ability of markers to differentiate health from IBS or IBS from other gastrointestinal diseases. 7 However, there are biomarkers that characterise or quantify a trait that is the target for treatment and, therefore, such biomarkers may facilitate selection of patients for inclusion in clinical trials, potentially facilitating drug development and reducing risks of adverse effects by only exposing patients who have a potential to respond to personalised therapy. With further validation, these biomarkers may also conceivably serve as surrogate endpoints 5 to appraise treatment efficacy in the clinical trials.
A logical approach to develop biomarkers in IBS focuses on important mechanisms or traits with relatively high prevalence (e.g. 25% or more) and selection of biomarkers that are actionable, that is, the trait can be altered or normalised by currently available or approved medications. The four most relevant classes of actionable targets are: serotonin, inflammation, colonic transit and bile acids. These principles will be described briefly.
(i) Serotonin is a signalling molecule involved in sensation, secretion, motor and platelet functions. Importantly, 95% of the body's serotonin is produced by gastrointestinal enteroendocrine cells, and there is a local re-uptake mechanism [serotonin transporter protein (SERT), also called solute carrier family 6 (neurotransmitter transporter), member 4 (SLC6A4)] that inactivates 5-HT after its release. Plasma levels of 5-HT in the postprandial period are increased in IBS-D or post-infectious IBS (that usually manifests as diarrhoea-predominant) and are lower in IBS-C compared to controls. 30, 31 The increased 5-HT in IBS-D provides the rationale for use of the 5-HT 3 receptor antagonist class of drugs, such as alosetron 47 and ondansetron. 33 The lower 5-HT in IBS-C provides the rationale for treatment with 5-HT 4 receptor agonists. 48 (ii) The role of immune activation and neuroimmune interactions in IBS has been reviewed elsewhere. 49 However, the prevalence of each of the immune activation mechanisms among IBS patients is unclear, and therapeutic approaches such as mast cell stabilisers, 50 One phase IIB study showed no significant change in bowel symptoms, although there is significant effect on adequate relief of IBS pain and discomfort AC, ascending colon; BA, bile acid; BM, bowel movements; CC, chronic constipation; CCK, cholecystokinin; Cl-C2, chloride channel type 2; CRH, corticotrophin releasing hormone; GLP-1, glucagon-like peptide 1; 5-HT, 5-hydroxytryptamine; IBS, irritable bowel syndrome; ITT, intention-to-treat; SB, small bowel; TTW, three times per week.
( Table 1 ). Such approaches have the potential to help identify homogeneous groups of patients for inclusion in clinical trials, reduce costs in drug development, and identify relevant subgroups responding to specific therapy. Similarly, several studies now demonstrate the utility of bile acid sequestrants and farnesoid X receptor agonist (obeticholic acid) for the management of BAM in IBS-D/functional diarrhoea, [61] [62] [63] including a first study that selected patients based on elevated total faecal BA excretion over 48 h. 62 
CONCLUSION
Treatment of IBS and lower functional gastrointestinal disorders is still based predominantly on symptoms; however, with greater understanding of the biology of the diseases and identification of biomarkers that reflect either the mechanism or manifestations of the pathophysiology, it is likely that significant advances will be made, leading to a renaissance in the field of IBS 4 and the individualisation of medical therapy. Among the proposed biomarkers in IBS, none of those proposed to date fulfill the expectations of diagnostic biomarkers, but, among proposed biomarkers in lower FGID, some are actionable, as they specifically reflect a quantitative difference in a mediator of dysfunction or result in a quantifiable disturbance of function that can be specifically treated. Such biomarkers may potentially identify relevant subgroups that respond to specific therapy. This principle of biomarker identification and use as target for treatment has been applied successfully for the mediator, serotonin and the class of secretagogues (lubiprostone, linaclotide) in scintigraphic measurement of colonic transit. Similarly, studies with 75 SeHCAT retention and 48-h faecal bile acid excretion have identified responders to bile acid sequestrants. Therefore, some biomarkers are ready for prime time because they have potential to identify subgroups of patients for inclusion in clinical trials targeting specific dysfunctions. Further experience with the use of these biomarkers to optimise efficacy in clinical trials and effectiveness in clinical practice will more firmly establish the concept of actionable biomarkers in IBS. By identifying subgroups with optimal responsiveness, these actionable biomarkers may ultimately help reduce costs in drug development and in the management of patients in clinical practice.
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